Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 15.8% in October

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 8,270,000 shares, a growth of 15.8% from the October 15th total of 7,140,000 shares. Currently, 11.4% of the shares of the company are sold short. Based on an average daily trading volume, of 463,300 shares, the days-to-cover ratio is currently 17.9 days.

Hedge Funds Weigh In On Invivyd

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of Invivyd by 3.9% in the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after purchasing an additional 97,496 shares during the period. State Street Corp boosted its holdings in shares of Invivyd by 3.7% in the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after buying an additional 35,904 shares during the period. Marshall Wace LLP increased its position in shares of Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after acquiring an additional 31,992 shares in the last quarter. Acadian Asset Management LLC raised its holdings in shares of Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after acquiring an additional 474,301 shares during the period. Finally, Duquesne Family Office LLC bought a new stake in Invivyd in the 2nd quarter valued at $629,000. Institutional investors own 70.36% of the company’s stock.

Invivyd Trading Down 4.5 %

IVVD stock traded down $0.04 during trading on Friday, hitting $0.76. The company had a trading volume of 563,067 shares, compared to its average volume of 632,977. The company has a fifty day moving average price of $0.99 and a two-hundred day moving average price of $1.30. The company has a market cap of $90.19 million, a P/E ratio of -0.39 and a beta of 0.65. Invivyd has a fifty-two week low of $0.76 and a fifty-two week high of $5.20.

Invivyd (NASDAQ:IVVD) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The company had revenue of $2.26 million during the quarter, compared to analyst estimates of $4.91 million. On average, analysts expect that Invivyd will post -0.6 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on IVVD shares. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Invivyd in a report on Tuesday, October 29th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.